Core Insights - Bio-Techne Corporation (TECH) is scheduled to release its first-quarter fiscal 2026 results on November 5, before market opening [1] - The company reported adjusted earnings per share (EPS) of 53 cents in the last quarter, exceeding the Zacks Consensus Estimate by 6.00%, with an average surprise of 9.22% over the last four quarters [1] Q1 Estimates for TECH - The Zacks Consensus Estimate for revenues is $289.3 million, reflecting a slight decrease of 0.04% from the previous year [2] - EPS is expected to remain flat at 42 cents year-over-year [2] Estimate Revision Trend - Earnings estimates have remained constant at 42 cents over the past 30 days [3] Factors Affecting Performance - Management indicated that macro uncertainties, including tariffs and potential NIH budget cuts, could slow growth momentum in Q1 fiscal 2026 [4] - The Protein Sciences division, which accounted for 72.5% of net sales in fiscal 2025, is expected to drive revenues through proteomic analytical tools and cell therapy workflow solutions [5] Product Portfolio and Growth - The core portfolio includes over 6,000 proteomic agents and 400,000 antibody types, supporting global customers in advancing therapeutics for precision diagnostics [6] - The protein analytical instrumentation business is anticipated to show strong momentum, continuing a trend of mid-teens year-over-year growth in instrument placements [7] - Demand for the next-generation high-throughput instrument, Leo, is expected to remain strong [8] Strategic Developments - A strategic distribution partnership with Sphere Bio will allow Bio-Techne to distribute ultrasensitive immunoassays for Alzheimer's disease biomarkers, potentially impacting Q1 revenues [9] Segment Performance - Protein Sciences revenues may rise due to strength in proteomic tools and cell therapy workflows, while Spatial Biology sales are likely to decline due to NIH funding concerns and project timing [10] - The consensus estimate for Spatial Biology revenues is $80.7 million, down 3% from the previous year [14] Challenges in Diagnostics and Spatial Biology - Organic revenues in the Diagnostics and Spatial Biology segment may have declined due to order timing and macro uncertainties affecting growth in the ExoDx prostate cancer test and diagnostic reagents business [12] - The Spatial Biology segment is facing headwinds from NIH funding uncertainty and a weaker biotech funding environment [13] Company Outlook - Bio-Techne has an Earnings ESP of -4.19%, indicating a lower chance of beating estimates [15] - The company currently holds a Zacks Rank of 3 (Hold) [16]